{
    "clinical_study": {
        "@rank": "55423", 
        "arm_group": [
            {
                "arm_group_label": "BVS857 Part A Open label", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "BVS857 Part A double blind", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo Part A double blind", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "BVS857 Part B double blind", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo Part B double blind", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if BVS857 is safe, tolerable and increases thigh\n      muscle thickness in patients with spinal bulbar and muscular atrophy (SBMA)."
        }, 
        "brief_title": "Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Spinal and Bulbar Muscular Atrophy", 
        "condition_browse": {
            "mesh_term": [
                "Muscular Atrophy", 
                "Atrophy", 
                "Bulbo-Spinal Atrophy, X-Linked", 
                "Muscular Disorders, Atrophic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Genetic diagnosis of SBMA with symptomatic muscle weakness\n\n          -  Able to complete 2 minute timed walk\n\n          -  Serum IGF-1 level less than or equal to 170 ng/mL\n\n        Exclusion Criteria:\n\n          -  Medically treated diabetes mellitus or known history of hypoglycemia\n\n          -  History of Bell's palsy\n\n          -  Treatment with systemic steroids > 10 mg/day (or equivalent dose); androgens or\n             androgen reducing agents; systemic beta agonists; or other muscle anabolic drugs\n             within the previous 3 months\n\n          -  History of cancer, other than non-melanomatous skin cancer\n\n          -  Retinopathy\n\n          -  Papilledema Other protocol defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02024932", 
            "org_study_id": "CBVS857X2202"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "BVS857 Part A Open label", 
                    "BVS857 Part A double blind"
                ], 
                "description": "BVS857 i.v. and escalating s.c. doses", 
                "intervention_name": "BVS857", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Part A double blind", 
                "description": "Placebo i.v. and s.c. doses", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BVS857 Part B double blind", 
                "description": "BVS857 s.c. doses", 
                "intervention_name": "BVS857", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Part B double blind", 
                "description": "Placebo s.c. doses", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 6, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20892"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Copenhagen", 
                        "country": "Denmark", 
                        "zip": "2100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ulm", 
                        "country": "Germany", 
                        "zip": "89081"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy", 
                        "state": "PD", 
                        "zip": "35128"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Denmark", 
                "Germany", 
                "Italy"
            ]
        }, 
        "number_of_arms": "5", 
        "official_title": "A Two-part Placebo-controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy(SBMA)", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of patients with adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "After 78 days in Part A and after 85 days in Part B."
            }, 
            {
                "measure": "Number of mild, moderate and severe adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "After 78 days in Part A and after 85 days in Part B."
            }, 
            {
                "measure": "Change in thigh muscle volume", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 85 in Part B."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02024932"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in score on the adult myopathy assessment tool.", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 85 in Part B."
            }, 
            {
                "measure": "Change in lean body mass.", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 85 in Part B."
            }, 
            {
                "measure": "Plasma Pharmacokinetics (PK) of BVS857: Observed maximum concentration following drug administration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Part A: days 1, 15, 29, 43, pre-dose, 1, 4, 12, 24, 48, 168 hours post-dose. On day 57, pre-dose. 1, 4, 12, 24, 48, 168, 504 hours post-dose. Part B: days 1 and 36, pre-dose, 4, 24, 48 hours post-dose. On day 78, pre-dose, 4, 24, 48, 168 hours post-dose."
            }, 
            {
                "measure": "Plasma Pharmacokinetics (PK) of BVS857: Time to reach the maximum concentration after drug administration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Part A: days 1, 15, 29, 43, pre-dose, 1, 4, 12, 24, 48, 168 hours post-dose. On day 57, pre-dose. 1, 4, 12, 24, 48, 168, 504 hours post-dose. Part B: days 1 and 36, pre-dose, 4, 24, 48 hours post-dose. On day 78, pre-dose, 4, 24, 48, 168 hours post-dose."
            }, 
            {
                "measure": "Plasma Pharmacokinetics (PK) of BVS857: The area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "Part A: days 1, 15, 29, 43, pre-dose, 1, 4, 12, 24, 48, 168 hours post-dose. On day 57, pre-dose. 1, 4, 12, 24, 48, 168, 504 hours post-dose. Part B: days 1 and 36, pre-dose, 4, 24, 48 hours post-dose. On day 78, pre-dose, 4, 24, 48, 168 hours post-dose."
            }, 
            {
                "measure": "Plasma Pharmacokinetics (PK) of BVS857: The area under the serum concentration-time curve from time zero to the end of the dosing interval tau (AUCtau)", 
                "safety_issue": "No", 
                "time_frame": "Part A: days 1, 15, 29, 43, pre-dose, 1, 4, 12, 24, 48, 168 hours post-dose. On day 57, pre-dose. 1, 4, 12, 24, 48, 168, 504 hours post-dose. Part B: days 1 and 36, pre-dose, 4, 24, 48 hours post-dose. On day 78, pre-dose, 4, 24, 48, 168 hours post-dose."
            }, 
            {
                "measure": "Plasma Pharmacokinetics (PK) of BVS857: The area under the serum concentration-time curve from time zero to infinity (AUCinf)", 
                "safety_issue": "No", 
                "time_frame": "Part A: days 1, 15, 29, 43, pre-dose, 1, 4, 12, 24, 48, 168 hours post-dose. On day 57, pre-dose. 1, 4, 12, 24, 48, 168, 504 hours post-dose. Part B: days 1 and 36, pre-dose, 4, 24, 48 hours post-dose. On day 78, pre-dose, 4, 24, 48, 168 hours post-dose."
            }, 
            {
                "measure": "Plasma Pharmacokinetics (PK) of BVS857: The terminal elimination half-life (T1/2)", 
                "safety_issue": "No", 
                "time_frame": "Part A: days 1, 15, 29, 43, pre-dose, 1, 4, 12, 24, 48, 168 hours post-dose. On day 57, pre-dose. 1, 4, 12, 24, 48, 168, 504 hours post-dose. Part B: days 1 and 36, pre-dose, 4, 24, 48 hours post-dose. On day 78, pre-dose, 4, 24, 48, 168 hours post-dose."
            }, 
            {
                "measure": "Compare dose normalized log-transformed AUCinf following IV and SC administrations.", 
                "safety_issue": "No", 
                "time_frame": "In Part A: days 1 and 15, pre-dose, 1, 4, 12, 24, 48, 168 hours post-dose."
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}